Literature DB >> 11292781

Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid.

A Boutonnier1, S Villeneuve, F Nato, B Dassy, J M Fournier.   

Abstract

The epidemic and pandemic potential of Vibrio cholerae O139 is such that a vaccine against this newly emerged serogroup of V. cholerae is required. A conjugate made of the polysaccharide moiety (O-specific polysaccharide plus core) of the lipopolysaccharide (LPS) of V. cholerae O139 (pmLPS) was prepared by derivatization of the pmLPS with adipic acid dihydrazide and coupling to tetanus toxoid (TT) by carbodiimide-mediated condensation. The immunologic properties of the conjugate were tested using BALB/c mice injected subcutaneously three times at 2 weeks interval and then a fourth time 4 weeks later. Mice were bled 7 days after each injection and then once each month for the following 6 months. LPS and TT antibody levels were determined by enzyme-linked immunosorbent assay using immunoplates coated with either O139 LPS or TT. Both pmLPS and pmLPS-TT conjugate elicited low levels of immunoglobulin M (IgM), peaking 5 weeks after the first immunization. The conjugate elicited high levels of IgG antibodies, peaking 3 months after the first immunization and declining slowly during the following 5 months. TT alone, or as a component of conjugate, induced mostly IgG antibodies. Antibodies elicited by the conjugate recognized both capsular polysaccharide and LPS from V. cholerae O139 and were vibriocidal. They were also protective in the neonatal mouse model of cholera infection. The conjugation of the O139 pmLPS, therefore, enhanced its immunogenicity and conferred T-dependent properties to this polysaccharide.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292781      PMCID: PMC98317          DOI: 10.1128/IAI.69.5.3488-3493.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  A J Lesse; A A Campagnari; W E Bittner; M A Apicella
Journal:  J Immunol Methods       Date:  1990-01-24       Impact factor: 2.303

2.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

3.  A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels.

Authors:  C M Tsai; C E Frasch
Journal:  Anal Biochem       Date:  1982-01-01       Impact factor: 3.365

4.  Alcian blue fixation allows silver staining of the isolated polysaccharide component of bacterial lipopolysaccharides in polyacrylamide gels.

Authors:  J Corzo; R Pérez-Galdona; M León-Barrios; A M Gutiérrez-Navarro
Journal:  Electrophoresis       Date:  1991-06       Impact factor: 3.535

5.  Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice.

Authors:  Z Kossaczka; J Shiloach; V Johnson; D N Taylor; R A Finkelstein; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

6.  Immunochemical characterization of an Ogawa-Inaba common antigenic determinant of Vibrio cholerae O1.

Authors:  Sylvain Villeneuve; Alain Boutonnier; Laurence A Mulard; Jean-Michel Fournier
Journal:  Microbiology       Date:  1999-09       Impact factor: 2.777

7.  Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.

Authors:  C Y Chu; B K Liu; D Watson; S S Szu; D Bryla; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

8.  Structural studies of the Vibrio cholerae O-antigen.

Authors:  L Kenne; B Lindberg; P Unger; B Gustafsson; T Holme
Journal:  Carbohydr Res       Date:  1982-03-01       Impact factor: 2.104

9.  Characterization of the lipopolysaccharide from Vibrio cholerae 395 (Ogawa).

Authors:  S Kabir
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

10.  Direct testing of blood culture for detection of the serotype 5 and 8 capsular polysaccharides of Staphylococcus aureus.

Authors:  A Boutonnier; F Nato; A Bouvet; L Lebrun; A Audurier; J C Mazie; J M Fournier
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

View more
  14 in total

1.  One-step immunochromatographic dipstick tests for rapid detection of Vibrio cholerae O1 and O139 in stool samples.

Authors:  F Nato; A Boutonnier; M Rajerison; P Grosjean; S Dartevelle; A Guénolé; N A Bhuiyan; D A Sack; G B Nair; J M Fournier; S Chanteau
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

Review 2.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

3.  Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.

Authors:  Julianne E Rollenhagen; Anuj Kalsy; Rina Saksena; Alaullah Sheikh; Mohammad Murshid Alam; Firdausi Qadri; Stephen B Calderwood; Pavol Kovác; Edward T Ryan
Journal:  Vaccine       Date:  2009-06-27       Impact factor: 3.641

4.  Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice.

Authors:  Julianne E Rollenhagen; Anuj Kalsy; Francisca Cerda; Manohar John; Jason B Harris; Regina C Larocque; Firdausi Qadri; Stephen B Calderwood; Ronald K Taylor; Edward T Ryan
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

Review 5.  Vibrio cholerae: lessons for mucosal vaccine design.

Authors:  Anne L Bishop; Andrew Camilli
Journal:  Expert Rev Vaccines       Date:  2011-01       Impact factor: 5.217

6.  Isolation, Purification, Characterization and Direct Conjugation of the Lipid A-Free Lipopolysaccharide of Vibrio cholerae O139.

Authors:  Peng Xu; Jana Korcová; Peter Baráth; Alžbeta Čížová; Jana Valáriková; Firdausi Qadri; Meagan Kelly; Robert D O'Connor; Edward T Ryan; Slavomír Bystrický; Pavol Kováč
Journal:  Chemistry       Date:  2019-08-20       Impact factor: 5.236

7.  Secondary acylation of Vibrio cholerae lipopolysaccharide requires phosphorylation of Kdo.

Authors:  Jessica V Hankins; M Stephen Trent
Journal:  J Biol Chem       Date:  2009-07-17       Impact factor: 5.157

8.  Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.

Authors:  Cyrille Grandjean; Alain Boutonnier; Bruno Dassy; Jean-Michel Fournier; Laurence A Mulard
Journal:  Glycoconj J       Date:  2008-07-23       Impact factor: 2.916

9.  Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Authors:  Daniel T Leung; Taher Uddin; Peng Xu; Amena Aktar; Russell A Johnson; Mohammad Arif Rahman; Mohammad Murshid Alam; Meagan Kelly Bufano; Grace Eckhoff; Ying Wu-Freeman; Yanan Yu; Tania Sultana; Farhana Khanam; Amit Saha; Fahima Chowdhury; Ashraf I Khan; Richelle C Charles; Regina C Larocque; Jason B Harris; Stephen B Calderwood; Pavol Kovác; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2013-03-20

10.  Use of a cholera rapid diagnostic test during a mass vaccination campaign in response to an epidemic in Guinea, 2012.

Authors:  Isabel Martinez-Pino; Francisco J Luquero; Kéïta Sakoba; Souleymane Sylla; Melatwork Haile; Rebecca F Grais; Iza Ciglenecki; Marie-Laure Quilici; Anne-Laure Page
Journal:  PLoS Negl Trop Dis       Date:  2013-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.